Article
Association of MDR1 C3435T and RFC1 G80A polymorphisms with methotrexate toxicity and response in Jordanian rheumatoid arthritis patients.
International journal of clinical pharmacology and therapeutics - 1 Sept 2014
Samara Sima A, Irshaid Yacoub M, Mustafa Khader N
Abstract excerpt
OBJECTIVES: Methotrexate (MTX) is the most commonly used disease-modifying antirheumatic drug for the treatment of rheumatoid arthritis (RA). Genetic polymorphisms of reduced folate carrier (RFC1 G80A) and multi-drug resistance-1 (MDR1 C3435T) might affect MTX response and/or toxicity. The aim of this study was to find out if there is an association between those polymorphisms and MTX toxicity and/or response in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
